“减肥神药”再登神坛：17600例三期临床成功，心血管风险降低20%_老虎社区_美港股上老虎

“减肥神药”再登神坛：17600例三期临床成功，心血管风险降低20%

医药笔记2023-11-12

司美格鲁肽坐实心血管获益效果。Armstrong2023年11月11日，诺和诺德在AHA会议上公布司美格鲁肽2.4mg剂量心血管获益三期临床SELECT最新数据，数据同步发表在新英格兰医学期刊（NEJM）上。SELECT入组17604例有既往心血管疾病肥胖/超重患者，随机分配接受司美格鲁肽或安慰剂治疗。司美格鲁肽组569例心血管死亡或非致病性stroke事件，对照组701例，心血管风险降低20%。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2382711635?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/903010d990786c782c161cadde49476c","is_english":false,"pubTime":"2023-11-12 09:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2382711635","market":"us","top_or_hot":-1,"title":"“减肥神药”再登神坛：17600例三期临床成功，心血管风险降低20%","media":"医药笔记","content":"<div>\n<p>司美格鲁肽坐实心血管获益效果。Armstrong2023年11月11日，诺和诺德在AHA会议上公布司美格鲁肽2.4mg剂量心血管获益三期临床SELECT最新数据，数据同步发表在新英格兰医学期刊（NEJM）上。SELECT入组17604例有既往心血管疾病肥胖/超重患者，随机分配接受司美格鲁肽或安慰剂治疗。司美格鲁肽组569例心血管死亡或非致病性stroke事件，对照组701例，心血管风险降低20%。...</p>\n\n<a href=\"https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247516596&idx=1&sn=f98926777c468f5168dfa9fa239e2db9&chksm=eb883a51dcffb3471572e0a86ae0da5a6ce5a6a8b774174e5154fb9d89000c89fe7a58fd4b20&mpshare=1&scene=23&srcid=11129Us0xRhg1hXYWz21NF9F&sharer_shareinfo=9486bb29880d79e8b90755e031c319de&sharer_shareinfo_first=9486bb29880d79e8b90755e031c319de#rd\">网页链接</a>\n\n</div>\n","source":"lsy1608539197933","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>“减肥神药”再登神坛：17600例三期临床成功，心血管风险降低20%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n“减肥神药”再登神坛：17600例三期临床成功，心血管风险降低20%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-12 09:53 北京时间&nbsp;&nbsp;&nbsp;<a href=https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247516596&idx=1&sn=f98926777c468f5168dfa9fa239e2db9&chksm=eb883a51dcffb3471572e0a86ae0da5a6ce5a6a8b774174e5154fb9d89000c89fe7a58fd4b20&mpshare=1&scene=23&srcid=11129Us0xRhg1hXYWz21NF9F&sharer_shareinfo=9486bb29880d79e8b90755e031c319de&sharer_shareinfo_first=9486bb29880d79e8b90755e031c319de#rd><strong>医药笔记</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>司美格鲁肽坐实心血管获益效果。Armstrong2023年11月11日，诺和诺德在AHA会议上公布司美格鲁肽2.4mg剂量心血管获益三期临床SELECT最新数据，数据同步发表在新英格兰医学期刊（NEJM）上。SELECT入组17604例有既往心血管疾病肥胖/超重患者，随机分配接受司美格鲁肽或安慰剂治疗。司美格鲁肽组569例心血管死亡或非致病性stroke事件，对照组701例，心血管风险降低20%。...</p>\n\n<a href=\"https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247516596&idx=1&sn=f98926777c468f5168dfa9fa239e2db9&chksm=eb883a51dcffb3471572e0a86ae0da5a6ce5a6a8b774174e5154fb9d89000c89fe7a58fd4b20&mpshare=1&scene=23&srcid=11129Us0xRhg1hXYWz21NF9F&sharer_shareinfo=9486bb29880d79e8b90755e031c319de&sharer_shareinfo_first=9486bb29880d79e8b90755e031c319de#rd\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247516596&idx=1&sn=f98926777c468f5168dfa9fa239e2db9&chksm=eb883a51dcffb3471572e0a86ae0da5a6ce5a6a8b774174e5154fb9d89000c89fe7a58fd4b20&mpshare=1&scene=23&srcid=11129Us0xRhg1hXYWz21NF9F&sharer_shareinfo=9486bb29880d79e8b90755e031c319de&sharer_shareinfo_first=9486bb29880d79e8b90755e031c319de#rd","article_id":"2382711635","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/903010d990786c782c161cadde49476c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2382711635","pubTimestamp":1699753981,"columns":[],"sourceInfo":{"source_id":"lsy1608539197933","name":"Armstrong的医药笔记"},"weMediaInfo":null,"summary":"司美格鲁肽组569例心血管死亡或非致病性stroke事件，对照组701例，心血管风险降低20%。心血管风险整体降低15%，心血管死亡风险降低15%，心衰复合终点风险降低18%，全因死亡风险降低19%。今年可谓司美格鲁肽的爆发之年，减肥药供不应求一再扩大产能，CKD疗效优异提前终止三期临床，心血管获益大规模三期临床大获成功等。此次MACE三期临床的成功，意味着司美格鲁肽坐实心血管获益效果，为其长期增长再添助力。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{},"translate_title":"\"Slimming medicine\" once again entered the altar: 17,600 cases were successfully clinically completed in Phase III, and the cardiovascular risk was reduced by 20%","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/a5ec4c187572ce71fef17bf8ab8cd010","symbols_score_info":{},"content_text":"司美格鲁肽坐实心血管获益效果。Armstrong2023年11月11日，诺和诺德在AHA会议上公布司美格鲁肽2.4mg剂量心血管获益三期临床SELECT最新数据，数据同步发表在新英格兰医学期刊（NEJM）上。SELECT入组17604例有既往心血管疾病肥胖/超重患者，随机分配接受司美格鲁肽或安慰剂治疗。司美格鲁肽组569例心血管死亡或非致病性stroke事件，对照组701例，心血管风险降低20%。NEJM文章发布了更详细的数据分析。患者基线数据如下。心血管获益从研究开始很快就显现，因此认为心血管获益不仅仅是因为体重减轻的附带劫夺。心血管风险整体降低15%，心血管死亡风险降低15%，心衰复合终点风险降低18%，全因死亡风险降低19%。支持性次要终点数据，非致命心梗风险降低28%，心衰住院或急诊率降低21%等。今年可谓司美格鲁肽的爆发之年，减肥药供不应求一再扩大产能，CKD疗效优异提前终止三期临床，心血管获益大规模三期临床大获成功等。总结诺和诺德基于对代谢疾病深刻理解，聚焦司美格鲁肽的多适应症开发，围绕肝脏、脑、肠道、胰脏，逐一将多个大适应症收入囊中。今年前三季度，司美格鲁肽大卖12亿美元，预计全年超过200亿美元。此次MACE三期临床的成功，意味着司美格鲁肽坐实心血管获益效果，为其长期增长再添助力。","kind":"news","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":10,"commentSize":0,"repostSize":1,"favoriteSize":8,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}